Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MDCX | PRESS-RELEASE | bullish | 6/10 | Medicus Pharma published the abridged Clinical Study Report for its Phase 2 SkinJect® trial on ClinicalTrials.gov, confi | Sep 10, 2026 |
| CRVO | PRESS-RELEASE | bullish | 5/10 | CervoMed announced that neflamapimod will be featured in a late-breaking oral presentation at the ISFTD Annual Meeting i | Sep 10, 2026 |
| PRLD | PRESS-RELEASE | neutral | 4/10 | Prelude Therapeutics announced FDA clearance to begin a Phase 1 study of PRT13722, an oral KAT6A selective degrader for | Sep 10, 2026 |
| TEVA | PRESS-RELEASE | neutral | 5/10 | Teva priced a ~$4.9B multi-tranche senior notes offering across five maturities (2032-2037), with proceeds to fund the c | Sep 10, 2026 |
| SAFX | 425 | bearish | 6/10 | XCF Global and DevvStream postponed their special meetings to vote on the proposed business combination with Southern En | Sep 10, 2026 |
| BHVN | 8-K | bearish | 7/10 | Biohaven disclosed that the FDA issued a partial clinical hold letter on September 4, 2026, pausing new patient enrollme | Sep 10, 2026 |
| INDP | 8-K | bearish | 7/10 | Indaptus Therapeutics entered into a stock purchase agreement for a $24M private placement of 20,338,974 shares, priced | Sep 10, 2026 |
| DNLI | CLUSTER | neutral | 2/10 | Three Denali insiders (COFO, Director, CMO) sold a total of ~$349K in open-market sales over a 5-day window. The aggrega | Sep 10, 2026 |
| TARS | CLUSTER | neutral | 3/10 | Three top insiders (CEO, COO, CMO) sold shares totaling ~$2.5M over a one-week window ending September 4, 2026. The tota | Sep 10, 2026 |
| ARTV | CLUSTER | bearish | 5/10 | A cluster of insider selling at Artiva Biotherapeutics, totaling $477K in open-market sales by the CEO, COO/CLO, CTO, an | Sep 10, 2026 |
| RLAY | CLUSTER | neutral | 4/10 | Two top executives at Relay Therapeutics, CEO Sanjiv Patel and President of R&D Donald Bergstrom, sold a combined $1.07M | Sep 10, 2026 |
| ASND | CLUSTER | neutral | 2/10 | Two Ascendis Pharma insiders sold a combined $873K in shares over a 7-day window, with the bulk ($811K) coming from SVP | Sep 10, 2026 |
| SLGL | INSIDER-BUY | bullish | 7/10 | Opaleye Management Inc., a 10% owner of Sol-Gel Technologies, executed a concentrated open-market buying spree totaling | Sep 10, 2026 |
| ARGX | INST-CLUSTER | mixed | 5/10 | A mixed institutional cluster in ARGX for 2026-Q2 shows 46 buyers accumulating $273.7M net, led by Capital Group ($82.1M | Sep 10, 2026 |
| ARWR | INST-CLUSTER | mixed | 5/10 | ARWR saw a mixed institutional cluster in Q2 2026 with 42 buyers accumulating $452.7M and 43 sellers reducing by $147.6M | Sep 10, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt sold ~$6.4M in open-market shares on the same day United Therapeutics announced a $477.6M accelera | Sep 10, 2026 |
| ALMS | INSIDER-BUY | bullish | 5/10 | Director Srinivas Akkaraju made a single open-market purchase of 220,070 shares of ALMS for $2.46M on September 4, 2026, | Sep 9, 2026 |
| KLRA | 3 | neutral | 1/10 | Nur Nicholson, newly appointed Chief Technology Officer of Kailera Therapeutics, filed a Form 3 initial statement of ben | Sep 9, 2026 |
| TRDA | CLUSTER | bearish | 6/10 | Two MPM BioVentures funds (10% owners) sold a combined $547K in TRDA shares over two days, part of a larger 7-day cluste | Sep 9, 2026 |
| BLTE | CLUSTER | bearish | 6/10 | CEO and CFO of Belite Bio sold a combined $837K in open-market sales on Sept 4, 2026, part of a larger 7-day cluster tot | Sep 9, 2026 |
| IRON | PRESS-RELEASE | bullish | 7/10 | Disc Medicine presented positive initial Phase 2 data for DISC-3405 in polycythemia vera (PV) at SOHO 2026, showing sign | Sep 9, 2026 |
| PPBT | 6-K | neutral | 2/10 | Purple Biotech Ltd. filed a 6-K on September 9, 2026, reporting the results of its Annual General Meeting of Shareholder | Sep 9, 2026 |
| CADL | 8-K | neutral | 4/10 | Candel Therapeutics filed an 8-K furnishing a September 2026 corporate investor presentation. The presentation highlight | Sep 9, 2026 |
| INM | 425 | neutral | 6/10 | InMed Pharmaceuticals filed a Rule 425 communication reporting FY2026 annual results and providing a corporate update on | Sep 9, 2026 |
| LLY | COURT-RULING | neutral | 4/10 | Eli Lilly's false advertising lawsuit against Mochi Health and compounding pharmacies survives in part. The court denied | Sep 9, 2026 |
| NVO | COURT-RULING | neutral | 1/10 | Novo Nordisk and defendant Aios Inc. (d/b/a Fella Health) entered a stipulated ESI discovery order in the Northern Distr | Sep 9, 2026 |
| NBP | 6-K | neutral | 3/10 | NovaBridge Biosciences reported the voting results of its 2026 Annual General Meeting, where shareholders approved the r | Sep 9, 2026 |
| TNXP | 8-K | neutral | 2/10 | Tonix Pharmaceuticals promoted Thomas Englese from EVP of Commercial Operations to Chief Commercial Officer, effective i | Sep 9, 2026 |
| XFOR | 8-K | bullish | 6/10 | X4 Pharmaceuticals announced a positive FDA Type C meeting outcome for its 4WARD Phase 3 chronic neutropenia trial. The | Sep 9, 2026 |
| KURA | 8-K | neutral | 2/10 | Kura Oncology appointed Jennifer Fulk as CFO, replacing Troy E. Wilson and Thomas Doyle in those roles, effective Septem | Sep 9, 2026 |